Abstract
Between September and December 2017, 82 men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia LUTS/BPH and prostate volume of 80–150 cc underwent Aquablation in a prospective multicenter clinical trial in the United States. Baseline patient and clinical demographics and standardized postoperative parameters were collected and tabulated in a central independently monitored database. Adverse events through 3 months were adjudicated by an independent clinical events committee. Mean pre-treatment prostate volume was 108 ± 21.1 cc. Mean operative time was 38.2 ± 14.4 min and mean Aquablation resection time was 7.7 ± 3.3 min. Additional electrocautery for hemostasis was not needed in any patient following Aquablation. The average length of stay following the procedure was 1.6 ± 1.0 days. Mean pre- and 3 months post-treatment IPSS scores were 23.7 ± 6.4 and 7.1 ± 5.1, –16.6, p < 0.01. Mean pre- and 3 months post-treatment Qmax were 9.2 ± 3.3 ml/s and 19.5 ± 13 ml/s, + 10.8 ml/s, p < 0.01. Mean pre- and 3 months post-treatment post-void residuals were 120.6 ± 119.1 cc and 50.6 ± 61.6 cc, –72.0 cc, p < 0.01. The observed Clavien-Dindo grade 2 or higher event rate at 3 months was 34.1%. Aquablation is a safe and effective treatment option for men with large prostates (80–150 cc) suffering from LUTS/BPH.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256–61.
McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122–8.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–803.
American Urological Association—Adult Urodynamics: AUA/SUFU Guideline [Internet]. [cited 3 Jul 3 2017]. Available from: https://www.auanet.org/guidelines/urodynamics. 2012
Ferretti M, Phillips J. Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. Can J Urol. 2015;22(Suppl 1):60–6.
Pariser JJ, Pearce SM, Patel SG, Bales GT. National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology . 2015;86:721–6.
Pariser JJ, Packiam VT, Adamsky MA, Bales GT. Trends in simple prostatectomy for benign prostatic hyperplasia. Curr Urol Rep. 2016;17:57.
Valdivieso R, Hueber P-A, Meskawi M, Belleville E, Ajib K, Bruyere F, et al. Multicenter international experience of 180W LBO laser photo-vaporization in men with extremely large prostates (prostate volume > 200 cc): Is there a size limit? Br J Urol. 2018 (In Press)
Hueber P-A, Bienz MN, Valdivieso R, Lavigueur-Blouin H, Misrai V, Rutman M, et al. Photoselective vaporization of the prostate for benign prostatic hyperplasia using the 180 watt system: Multicenter study of the impact of prostate size on safety and outcomes. J Urol. 2015;194:462–9.
Brunckhorst O, Ahmed K, Nehikhare O, Marra G, Challacombe B, Popert R. Evaluation of the learning curve for holmium laser enucleation of the prostate using multiple outcome measures. Urology . 2015;86:824–9.
Robert G, Cornu J-N, Fourmarier M, Saussine C, Descazeaud A, Azzouzi A-R, et al. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int. 2016;117:495–9.
Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation—image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117:923–9.
Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol. 2017;197:1565–72.
Gilling PJ, Barber NJ, Bidair M, Anderson P. WATER—A double-blind randomized controlled trial of aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia. J Urol. 2018;199:1252–1261.
Desai M. Bidair M, Bhojani N. WATER II Aquablation procedural outcomes for BPH in large prostates (80–150cc): Initial experience. Br J Urol. 2018 (In Press).
R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R foundation for statistical computing; 2016. Available from: https://www.R-project.org/
Gratzke C, Schlenker B, Seitz M, Karl A, Hermanek P, Lack N, et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol. 2007;177:1419–22.
Lanchon C, Fiard G, Long J-A, Arnoux V, Carnicelli D, Franquet Q, et al. Open prostatectomy versus 180-W XPS GreenLight laser vaporization: Long-term functional outcome for prostatic adenomas > 80g. Prog En Urol [Internet]. 2018 Jan 10 [cited 2018 Jan 20]; Available from: http://www.sciencedirect.com/science/article/pii/S1166708717306826
Hueber P-A, Liberman D, Ben-Zvi T, Woo H, Hai MA, Te AE, et al. 180 W vs 120 W lithium triborate photoselective vaporization of the prostate for benign prostatic hyperplasia: a global, multicenter comparative analysis of perioperative treatment parameters. Urology. 2013;82:1108–13.
Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172(5 Pt 1):1926–9.
Kuo RL, Paterson RF, Siqueira TM, Watkins SL, Simmons GR, Steele RE, et al. Holmium laser enucleation of the prostate: morbidity in a series of 206 patients. Urology . 2003;62:59–63.
Bachmann A, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study. Eur Urol. 2014;65:931–42.
Kuntz RM, Ahyai S, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol. 2004;172:1012–6.
Tan AHH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003;170(4 Pt 1):1270–4.
Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol. 2013;189(1 Suppl):S141–5.
Acknowledgements
The study was funded by PROCEPT BioRobotics.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Yafi, F.A., Tallman, C.T., Seard, M.L. et al. Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc). Int J Impot Res 30, 209–214 (2018). https://doi.org/10.1038/s41443-018-0045-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-018-0045-3
This article is cited by
-
Long-Term Failure Rates Among Interventions for Benign Prostatic Obstruction
Current Bladder Dysfunction Reports (2024)
-
Technique, outcome and changes in prostate dimensions in patients with urinary retention managed by aquablation
International Urology and Nephrology (2022)
-
“Doc, if it were you, what would you do?”: a survey of Men’s Health specialists’ personal preferences regarding treatment modalities
International Journal of Impotence Research (2021)
-
A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia
Wiener klinische Wochenschrift (2021)
-
Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study
Prostate Cancer and Prostatic Diseases (2020)